Obstructive sleep apnea
OSA · CVRM · 2 drugs · 1 indications
Sleep disorder with repeated breathing interruptions. Associated with obesity and cardiovascular risk.
Competitive Landscape (2 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| MariTide | AMGN | GLP-1 agonist / GIP antagonist (bispecific) | Antibody-peptide conjugate | SC | PHASE3 |
| Zepbound | LLY | GLP-1/GIP dual agonist | Peptide | SC | APPROVED |
Indications (1)
Upcoming Catalysts
MariTide - Obesity - Ph2 Part 2 - Maintenance/Quarterly Dosing DataCLINICAL
AMGNH1 2026
Tirzepatide - MASH - Ph3 - Topline (SYNERGY-NASH)CLINICAL
LLY2026
Zepbound - Medicare Part D AccessCOMMERCIAL
LLYJuly 1, 2026
Zepbound vs CagriSema - Obesity - Ph3 - Topline (REDEFINE-4)CLINICAL
LLYH2 2026
MariTide - T2D + Obesity - Ph3 - Topline (MARITIME-2)CLINICAL
AMGNEarly 2027
MariTide - Obesity - Ph3 - Topline (MARITIME-1)CLINICAL
AMGNEarly 2027
MariTide - Obesity - BLA FilingREGULATORY
AMGN2027-2028
MariTide - HFpEF - Ph3 - Outcomes (MARITIME-HF)CLINICAL
AMGN2028+
Data from Supabase · Updated 2026-03-24